Casimersen

Chemical structure of Casimersen

Casimersen is a medication used in the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. Casimersen is specifically designed for patients with a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

Mechanism of Action

Casimersen is an antisense oligonucleotide that targets exon 45 of the dystrophin gene. By binding to this specific exon, Casimersen induces exon skipping during mRNA processing, which allows for the production of a truncated but functional dystrophin protein. This mechanism aims to restore the production of dystrophin, which is deficient in patients with Duchenne muscular dystrophy.

Administration

Casimersen is administered via intravenous infusion. The dosing regimen is typically once weekly, and the dosage is based on the patient's weight. The treatment is usually continued as long as the patient shows clinical benefit and does not experience unacceptable side effects.

Side Effects

Common side effects of Casimersen include:

• Headache
• Fever
• Cough
• Upper respiratory tract infection

Serious side effects may include kidney toxicity, and regular monitoring of kidney function is recommended during treatment.

Clinical Trials

Casimersen has undergone clinical trials to evaluate its efficacy and safety in patients with Duchenne muscular dystrophy. These trials have demonstrated that Casimersen can increase dystrophin production in muscle tissue, which is associated with improved clinical outcomes in some patients.

Related Pages

• Duchenne muscular dystrophy
• Antisense oligonucleotide
• Exon skipping
• Dystrophin